Physician profile
James D Mackey
NPI 1356388870
$265,496.60
in general payments reported to CMS, 2019-2025
78 companies · $1,068 in 2025
The $1,068 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $27K · 2021: $100K · 2022: $9,094 · 2023: $8,113 · 2024: $442 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,608 · Food and Beverage: $2,104 · Travel and Lodging: $1,515 · Consulting Fee: $900 · Long Term Medical Supply Or Device Loan: $299 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,607.50 |
| Food and Beverage | $2,104.09 |
| Travel and Lodging | $1,515.27 |
| Consulting Fee | $900.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $238,172.48 | 2019-2023 | Injectafer |
| Heron Therapeutics, INC. | $6,768.67 | 2019-2022 | |
| Celgene Corporation | $5,526.60 | 2019-2025 | Breyanzi |
| Pharmacosmos Therapeutics INC. | $3,433.62 | 2020-2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $1,218.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $998.68 | 2019-2025 | Opdivo |
| Amgen INC. | $964.36 | 2019-2023 | Kyprolis |
| Seagen INC. | $806.20 | 2019-2024 | Tukysa |
| Astrazeneca Pharmaceuticals Lp | $697.36 | 2019-2023 | Imfinzi |
| Merck Sharp & Dohme LLC | $530.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $517.48 | 2019-2025 | |
| Genzyme Corporation | $389.42 | 2019-2023 | |
| Janssen Biotech, INC. | $388.96 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Lilly USA, LLC | $372.80 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $321.86 | 2019-2023 | Rezlidhia, Tavalisse |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.